You are here: Home > Institute of Excellence (CPD) > CPD Events > Progress in Geographic Atrophy Treatment Approvals in Australia

Progress in Geographic Atrophy Treatment Approvals in Australia

Date: 5/08/2026 (AEST)

Venue: https://www.carinaleaguesclub.com.au/functions/, QLD, 4152

Provider: LVF Ophthalmology Research Centre

Contact: Michelle Carley-Lep, [E] admin@lvfeyecentre.org.au, [P] 07 3398 9494

Activity Outline

Geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration, has shifted from an untreatable diagnosis to one with two TGA-approved complement-inhibitor therapies: pegcetacoplan (Syfovre), registered in January 2025, and avacincaptad pegol (Izervay), registered in October 2025. This session moves beyond the headlines to give optometrists a practical, evidence-based framework for the new era of dry AMD co-management.

We begin with the Australian access reality - TGA registration, current PBS/PBAC status, and what this means for patient counselling and out-of-pocket considerations. From there, the focus turns to where optometrists add the greatest value: detecting GA earlier and referring at the right moment.

The core of the session is an OCT biomarker masterclass - moving beyond fundus autofluorescence pattern recognition to the structural signs that precede irreversible atrophy: incomplete and complete RPE and outer retinal atrophy (iRORA/cRORA), choroidal hypertransmission, outer retinal subsidence, intraretinal hyperreflective foci, and ellipsoid zone loss. We examine why the subfoveal versus non-subfoveal distinction inverts clinical intuition, and why a patient with 6/6 vision may be the most urgent referral.

We address the field honestly: the structural–functional paradox (slowed lesion growth without proven visual acuity benefit), the macular neovascularisation conversion risk, and a balanced appraisal of both approved agents. Interactive OCT-based cases let participants test their own "refer, monitor, or reassure" reasoning. Finally, we preview the pipeline - gene therapy and oral complement inhibition - that may redefine treatment burden within this decade.

Participants will leave with a clear referral framework and the diagnostic confidence to identify treatable GA before central vision is lost.

Learning Objectives

  • Describe the current TGA approval and PBS reimbursement status of pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) for geographic atrophy in Australia.
  • Identify key OCT biomarkers of early and progressive geographic atrophy — including iRORA, cRORA, choroidal hypertransmission, hyperreflective foci, and ellipsoid zone loss — using standard practice imaging.
  • Differentiate subfoveal from non-subfoveal GA lesions and explain how lesion location, focality, and growth rate influence treatment candidacy and referral urgency.
  • Critically appraise the efficacy and safety evidence for complement-inhibitor therapy, including the structural–functional paradox and the risk of conversion to neovascular AMD.
  • Apply an evidence-based referral framework to determine which GA patients to refer, monitor, or reassure in a co-management setting.

Max CPD hours awarded: 2.5

Session Information

Name
Progress in Geographic Atrophy Treatment Approvals in Australia
Clinical?
Yes
Interactive?
Yes
Therapeutic?
Yes
Duration of CPD Session/Module
2.5
Duration of CPD Session/Module inclusive of Assessment Component
2.5

Acknowledgement of Country

In the spirit of reconciliation Optometry Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.